Bio-Rad Introduces SsoAdvanced™ Universal Inhibitor-Tolerant SYBR® Green Supermix

Date: 
07/09/2014

New Reagent Delivers Quality qPCR Data from Samples that Are Challenging To Amplify

Hercules, CA — July 10, 2014 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announces the launch of the SsoAdvanced™ Universal Inhibitor-Tolerant SYBR® Green Supermix, a proven solution for obtaining reproducible, optimal-quality qPCR data from the most challenging samples. 

Generating quality qPCR data from difficult-to-amplify samples such as crude lysates from plants, tissues, formalin-fixed paraffin-embedded samples, and other less-than-ideal sources that contain PCR inhibitors can be challenging and frustrating. In these situations, PCR may be greatly inhibited, making it nearly impossible for researchers to obtain reliable data, wasting time and money.

SsoAdvanced™ Universal Inhibitor-Tolerant SYBR® Green Supermix provides all of the advantages of other Bio-Rad supermixes with the added benefit of inhibitor tolerance.

The formulation of the SsoAdvanced™ Universal Inhibitor-Tolerant SYBR® Green Supermix has been optimized and validated to tolerate a wider spectrum of PCR inhibitors than competing SYBR® Green reagents. These inhibitors include those found in crude lysates, polysaccharides and polyphenols, and various reagents left over from sample prep such as ethanol, isopropanol, EDTA, and sodium chloride (see performance data for all inhibitors).

As with all SsoAdvanced Supermixes, the inhibitor-tolerant version includes Bio-Rad’s Sso7d-fusion polymerase, which is engineered for enhanced qPCR performance. The supermix is compatible with all real-time PCR instruments and functions under any reaction condition.

Visit www.bio-rad.com/SUIT1 to learn more about SsoAdvanced™ Universal Inhibitor-Tolerant SYBR® Green Supermix.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has been at the center of scientific discovery for 60 years, manufacturing and distributing a broad range of products for life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and industry customers through its global network of operations. The company employs approximately 7,750 people worldwide and had revenues exceeding $2.1 billion in 2013. Visit us at www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information contact:
Sam Ropp
Bio-Rad
510-741-6528
Sam_Ropp@bio-rad.com

Ken Li
Chempetitive Group
312-997-2436 x 112
kli@chempetitive.com